News

There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.

The good

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

There are several reasons many investors gravitate toward dividend stocks. Some are attracted to the regular income stream, while others opt for dividend reinvestment to boost long-term returns

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

Think small. It's one of the best ideas for investors seeking to reap returns that trounce the overall market.

Three Motley Fool contributors identified small-cap stocks that they think could

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end